Table 11.

Mean maximum decreases from baseline for standing blood pressure and mean maximum increases from baseline for standing pulse rate over 0–4 h postdose (study 2)

Dose group	Day	SBP (mmHg)	DBP (mmHg)	PR (bpm)
3 mg b.i.d.	1	−4.14	−8.90	1.90
	7	−9.94	−5.70	2.10
	12	−6.34	−2.90	18.90
10 mg b.i.d.	1	−6.23	−6.37	5.57
	7	−5.23	−4.37	6.17
	12	−10.23	−8.17	12.97
25 mg b.i.d.	1	−9.85	−6.35	−2.47
	7	−6.65	−4.02	1.75
	12	−7.02	−3.77	6.00
100 mg b.i.d.	1	−8.72	−5.09	7.63
	7	−8.39	−0.54	7.74
	12	−5.28	−3.09	9.96
300 mg b.i.d.	1	−12.75	−7.84	5.98
	7	−17.42	−7.84	10.20
	12	−16.08	−7.40	7.65
600 mg q.d. (cohort 3)	1	−12.97	−8.92	12.56
	7	−25.64	−17.36	21.23
	12	nd	nd	nd
600 mg q.d. (cohort 5)	1	−13.12	−11.10	11.35
	7	−18.90	−12.88	19.91
	12	−15.34	−14.10	13.91
Placebo	1	−11.27	−5.59	5.20
	7	−11.86	−6.36	9.38
	12	−9.76	−5.83	11.71

DBP, diastolic blood pressure; nd, not determined; PR, pulse rate; SBP, systolic blood pressure.